Phase 2
Phase 2 clinical trials administer the experimental medicine or treatment to a larger group of people (100–300). These clinical trials gather preliminary data on whether a medicine works in people who have a certain condition/disease. For example, participants receiving the medicine may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different medicine. Safety continues to be evaluated, and short-term adverse events are studied. (CTG)
